Cookies are used for the functionality of our web site. For more information
please see our Privacy policy or Ok thanks
Share:          
 

COVID-19
video reports

COVID-19 updates

 

19 January 2022

European Journal of Public Health - SUPPLEMENT
Guest editors: Dineke Zeegers Paget, Iveta Nagyova, Peter Allebeck

European Journal of Public Health - SUPPLEMENT videos
In order to make those articles accessible to most, we have asked the authors of the articles to present the background and main findings of their articles in 2 minutes subtitled videos. Access them below!

14 January 2022

ECDC
Weekly epidemiological update: Omicron variant of concern (VOC) – week 2 (data as of 13 January 2022) EU/EEA

7 January 2022

ECDC
ECDC updates its guidance regarding quarantine and isolation considering the rapid spread of Omicron in the EU/EEA

Considering the rapid spread of the Omicron variant of concern, ECDC is proposing options regarding quarantine and isolation, and recommendations that can be adapted and implemented by EU/EEA Member States when resources are limited and when there is high pressure on healthcare systems and other functions in society (e.g. staff shortage and reduced resources). Due to limited scientific evidence on the epidemiological characteristics of Omicron, the proposed options are not evidence based and may imply an additional risk for transmission.

The BMJ 
Covid-19: Fourth vaccine doses—who needs them and why?

3 January 2022

ECDC 
COVID-19 situation update for the EU/EEA, as of 3 January 2022

The BMJ
Covid-19: An urgent call for global “vaccines-plus” action

"A vaccines-plus approach should be adopted globally. This strategy will slow the emergence of new variants and ensure they exist in a low transmission background where they can be controlled by effective public health measures, while allowing everyone (including those clinically vulnerable) to go about their lives more freely."

20 December 2021

ECDC 
Methods for the detection and characterisation of SARS-CoV-2 variants - first update

This technical report provides guidance to laboratories, microbiology experts and relevant stakeholders in making decisions on establishing or scaling up capability and capacity to detect and identify circulating SARS-CoV-2 variants. It will also facilitate decision-making on the appropriate technologies to use and for which objective.

The Lancet
Diagnostics for COVID-19: moving from pandemic response to control

In this paper, authors discuss how the role of diagnostics in both clinical medicine and control of the pandemic has evolved over time with increased knowledge about the SARS-CoV-2 virus and its mode of transmission, and the understanding that it is destined to become endemic.

7 December 2021

EMA
EMA and ECDC recommendations on heterologous vaccination courses against COVID-19

In order to provide scientific grounds and further provide flexibility to vaccination schemes EMA and ECDC, in collaboration with EU experts in EMA’s COVID-ETF group, have reviewed the available evidence, and provided technical recommendations and advice on heterologous vaccination against COVID-19, either in the primary course or as a booster.

3 December 2021

Read the latest update on Omicron from ECDC.  

1 December 2021

European Commission 
Communication: Addressing together current and new COVID-19 challenges

Communication of the Commission to the European Parliament, the Council, the European Economic and Social Committee and the Committee of the Regions on Adressing together current and new COVID-19 challenges.

26 November 2021

European Commission
EU replaces COVID-19 vaccines export authorisation mechanism with new monitoring tool

The EU will not extend the COVID-19 vaccines export transparency and authorisation mechanism, which expires on 31 December 2021. This means that, as of 1 January 2022, vaccine producers will no longer have to request an authorisation for the export of vaccines outside the EU.

25 November 2021

European Commission
COVID-19 Travel and health measures in the EU

Factsheet

24 November 2021

ECDC
Assessment of the current SARS-CoV-2 epidemiological situation in the EU/EEA, projections for the end-of-year festive season and strategies for response, 17th update

"The current epidemiological situation is to a large part driven by the high transmissibility of the Delta variant that counteracts the reduction in transmission achieved by the current vaccination rollout in the EU/EEA."

ECDC statement: Risk of very high COVID-19 burden unless public health measures are applied urgently

"We have safe and effective vaccines available and until a larger part of the eligible population is immunised, non-pharmaceutical interventions must continue to remain part of our daily routine." says Andrea Ammon, ECDC Director. 

11 November 2021

BMJ
[VIDEO] Covid unknowns: Population and herd immunity

EMA
COVID-19: EMA recommends authorisation of two monoclonal antibody medicines

EMA’s human medicines committee (CHMP) has recommended authorising Ronapreve (casirivimab/imdevimab) and Regkirona (regdanvimab) for COVID-19.

ECDC
Overview of the implementation of COVID-19 vaccination strategies and deployment plans in the EU/EEA

This report provides an updated overview of the progress of national COVID-19 vaccination strategies and deployment in European Union/European Economic Area (EU/EEA) countries, including updates on:

- overall vaccine uptake and uptake by target group;
- vaccination strategies and policies;
- challenges and good practice with the rollout, including vaccine acceptance and uptake.

10 November 2021

ECDC
New update of the ECDC COVID-19 Vaccine Tracker

On 10 November 2021 ECDC released an updated version of its COVID- 19 Vaccine Tracker with additional information, new indicators, and improved features for visualisation. 

9 November 2021

ECDC
[VIDEO] Five C's to boost COVID-19 vaccination

Confidence - Constraints - Complacency - Calculation - Collective responsibility.
These "five C's" have a major influence on one's decision on vaccination. How can we raise the COVID-19 vaccine uptake and acceptance?
John Kinsman, ECDC's expert on Social an Behaviour change, explains.

OECD
The health impact of COVID-19

Find out more about the health impact of COVID-19 in the Health at a Glance 2021 report from the OECD.

3 November 2021

WHO
WHO issues emergency use listing for eighth COVID-19 vaccine

On November 3rd, the World Health Organization (WHO) issued an emergency use listing (EUL) for COVAXIN® (developed by Bharat Biotech), adding to a growing portfolio of vaccines validated by WHO for the prevention of COVID-19 caused by SARS-CoV-2.

26 October 2021

ECDC
ECDC publishes updated technical report on Options for the use of rapid antigen detection tests for COVID-19 in the EU/EEA

The European Centre for Disease Prevention and Control (ECDC) has published the first update of the technical report Options for the use of rapid antigen detection tests (RADTs) for COVID-19 in the EU/EEA, originally released in November 2020. 
In conclusion, ECDC considers that appropriately validated RADTs, which are part of the HSC list, could be used to certify that a person has recovered from a past COVID-19 infection. However, self-test RADTs should not be used for issuing a formal certificate as proper sampling is crucial for diagnosis, and if testing is not performed correctly, a reliable test cannot be assured.

22 October 2021

European Commission
European Health Union: Commission establishes portfolio of 10 most promising treatments for COVID-19

Delivering on a key action from the EU Strategy on COVID-19 Therapeutics, the Commissionhas established a portfolio of 10 potential COVID-19 therapeutics. The list established is based on independent scientific advice, and focuses on COVID-19 treatment candidates that are likely to be authorised and therefore available on the European market soon. 

21 October 2021

WHO/Europe
One billion COVID-19 vaccine doses administered in the WHO European Region – but risks for the unvaccinated leave no room for complacency

'COVID-19 vaccines have been developed to save lives, not to eliminate the virus and halt its transmission. Yet, the more people who get vaccinated the easier it is to bring transmission under control. Reaching 70% coverage everywhere is still our goal if we wish to stabilize the crisis.'

18 October 2021

ECDC
COVID-19 surveillance guidance - Transition from COVID-19 emergency surveillance to routine surveillance of respiratory pathogens

This publication offers practical guidance to EU/EEA countries, encouraging them to transition from emergency surveillance for COVID-19 to more sustainable, objective-driven, surveillance systems. 

15 October 2021

ECDC
Facilitating COVID-19 vaccination acceptance and uptake in the EU/EEA

This technical report presents considerations for European Union/European Economic Area (EU/EEA) countries when diagnosing barriers to acceptance and uptake of COVID-19 vaccination, and designing and implementing interventions to increase uptake.

8 October 2021

ECDC
ECDC builds study infrastructure to monitor COVID-19 vaccine effectiveness

ECDC is creating new infrastructure to allow for regular monitoring and analysis of COVID-19 vaccine effectiveness (VE) over time, using a multi-country approach, through the implementation of studies in different settings. One of these settings is hospitals, where the primary aim is to assess vaccine effectiveness against severe disease. 

EJPH
SARS-CoV-2 outbreaks on Danish mink farms and mitigating public health interventions

SARS-CoV-2 infections among farmed mink in Denmark significantly link to local human infection trends. Strict animal and human disease surveillance in regions with mink farming should be pursued internationally to mitigate future epidemic developments.

7 October 2021

The Lancet Regional Health Europe
Multi-country collaboration in responding to global infectious disease threats: lessons for Europe from the COVID-19 pandemic

In this Health Policy article, authors examine the case for multilateral collaboration on threats from infectious disease. While recognising that there are many perspectives we could adopt, including those from the international relations literature, they begin with the economic case for collaboration, looking at two types of goods with substantial inter-country effects: shared knowledge and population immunity.

Euractiv / Reuteurs
New EU travel map to be based on vaccination rates

The ECDC is proposing a revision of COVID-19 rules which could ease travel for vaccinated people and drop a colour-coded system that limits trips to and from areas with high levels of infections.

Journal of Epidemiology and Community Health
Job loss and lower healthcare utilisation due to COVID-19 among older adults across 27 European countries

The aim of this study was to examine the prevalence and predictors of COVID-19-related unemployment and healthcare utilisation in a sample of older adults across 27 European countries. In conclusion, job loss and lower healthcare utilisation for non-COVID-19-related reasons were common among older adults and were associated with several sociodemographic characteristics. Job loss appeared to disproportionally affect already economically vulnerable individuals, raising concerns about the exacerbation of social inequalities.

5 October 2021

The BMJ Opinion
Unpacking vaccine “hesitancy:” the spectrum of vaccine acceptance

'Not everyone who is not ready to have a vaccine is an “anti-vaxxer” and only by acknowledging this, working with diverse communities and understanding the range of people’s concerns are we likely to win them over to the side of public health interventions.'

30 September 2021

ECDC
Rapid Risk Assessment: Assessing SARS-CoV-2 circulation, variants of concern, non-pharmaceutical interventions and vaccine rollout in the EU/EEA, 16th update

The risk assessed in this update is as follows: based on current levels of vaccination coverage and the dominance of the Delta variant in the EU/EEA, what risk does SARS-CoV-2 pose to the general population and the vulnerable population in the coming months?

27 September 2021

The BMJ Global Health
Characterising long COVID: a living systematic review

This study aims to regularly synthesise evidence on long COVID characteristics, to help inform clinical management, rehabilitation strategies and interventional studies to improve long-term outcomes.

 
This study explores the views and experiences of scientists working on government advisory boards during the COVID-19 pandemic, with the aim to learn lessons for future pandemic management and preparedness.

23 September 2021

ECDC
Overview of the implementation of COVID-19 vaccination strategies and deployment plans in the EU/EEA

This report provides an updated overview of the progress of national COVID-19 vaccination strategies in EU/EEA countries, including updates on: vaccine uptake overall and by target group; current vaccination phases and priority groups, as well as any adjustments made to priority groups during the rollout; vaccination strategies and policies in place; and the use of vaccination certificates and challenges countries face with the rollout and good practices to mitigate these challenges.

The BMJ
Covid-19 vaccination: evidence of waning immunity is overstated

In conclusion, the risks of remaining unvaccinated are clear and far outweigh the unknown benefits of re-vaccinating the general population. Rapid scale-up of vaccination coverage globally remains the most urgent public health priority.

15 September 2021

Nature
The fight to manufacture COVID vaccines in lower-income countries

Drug companies and wealthy countries are facing increased pressure to partner with firms in the global south but are reluctant to relinquish control. 

11 September 2021

European Journal of Public Health
Social distancing measures: barriers to their implementation and how they can be overcome – a systematic review

This review identifies the need for good communication as well as the need for authorities to provide comprehensive support as two key opportunities to increase acceptability and adherence. 

3 September 2021

ECDC
ECDC awards 77 M€ to strengthen EU/EEA Member States’ capacities to detect and identify SARS-CoV-2 variants

ECDC has awarded more than 77 M€ to 24 EU/EEA countries to strengthen whole genome sequencing and RT-PCR infrastructures within the countries’ national public health programmes. 

2 September 2021

European Journal of Public Health
COVID-19 vaccines a global public good? Moving past the rhetoric and making work of sharing intellectual property rights, know-how and technology

'In spite of the fact that vaccines were soon crowned ‘global public goods’, little came of it in reality, and low-income countries are dependent on inadequate donation-based systems. Key in changing the tide is to ensure better global access, for which more vaccines must become available. To this end, Intellectual property (IP) rights, know-how and technology must be shared to maximize vaccine production.'

1 September 2021

ECDC
Interim public health considerations for the provision of additional COVID-19 vaccine doses

This document aims to provide the target audience with interim public health considerations for the provision of additional COVID-19 vaccine doses. 

31 August 2021

European Commission
Coronavirus: 70% of the EU adult population fully vaccinated

On August 31st, the EU has reached a crucial milestone with 70% of the adult population now fully vaccinated. In total, over 256 million adults in the EU have now received a full vaccine course. Seven weeks ago already, the Commission's delivery target was met, ahead of time: to provide Member States, by the end of July, with enough vaccine doses to fully vaccinate 70% of the adult EU population.

24 August 2021

Nature
Monitoring non-pharmaceutical public health interventions during the COVID-19 pandemic

Measuring and monitoring non-pharmaceutical interventions is important yet challenging due to the need to clearly define and encode non-pharmaceutical interventions, to collect geographically and socially representative data, and to accurately document the timing at which interventions are initiated and changed. These challenges highlight the importance of integrating and triangulating across multiple databases and the need to expand and fund the mandate for public health organizations to track interventions systematically.

17 August 2021

Nature
The WHO is right to call a temporary halt to COVID vaccine boosters

'If vaccines were not scarce, boosters would be less controversial. But to focus on boosters when more than half the world lacks vaccine doses is short-sighted and will only keep the pandemic burning longer. For wealthy countries, this strategy means they will be indefinitely chasing their tails in terms of new variants. And for the rest of the world, it means prolonging unnecessary suffering.'

12 August 2021

WHO
WHO Statement on advancing the next series of studies to find the origins of SARS-CoV-2

The International Scientific Advisory Group for Origins of Novel Pathogens, or SAGO, is a new advisory group for WHO, which will be responsible for advising WHO on the development of a global framework to systematically study the emergence of future emerging pathogens with pandemic potential. For SARS-CoV-2, it will support the rapid undertaking of recommended studies outlined in the March 2021 report. 

10 August 2021

The Lancet Public Health
Effects of adjusting public health, travel, and social measures during the roll-out of COVID-19 vaccination: a modelling study

In this paper, authors aimed to evaluate to what extent travel restrictions and other PHSMs can be relaxed without exacerbating the local and global spread of COVID-19.

9 August 2021

The BMJ
Covid-19: How effective are vaccines against the delta variant?

'While it’s sobering to see cases occurring in fully vaccinated people, their protection is holding up well, as judged by numbers of hospital admissions and fatalities relative to what might have been. As Iwasaki puts it: the message should still be to get vaccinated as soon as possible.'

The Lancet
Towards a European strategy to address the COVID-19 pandemic

'The pandemic is yet to be overcome, but an end is conceivable. Restrictions can be lifted when high vaccination coverage is reached, and if vaccines remain highly effective against VOCs. However, until then, the goal should be to minimise economic and societal costs for Europe and for the world. Maintaining and communicating a clear strategy is key, and pan-European coordination and common goals across countries are more important than ever.'

The Lancet Digital Health
Predicted COVID-19 positive cases, hospitalisations, and deaths associated with the Delta variant of concern, June–July, 2021

Building on methods previously described in the context of the first and second waves in largely unvaccinated individuals, authors developed a prediction model that estimates the likelihood of hospitalisation and deaths of people currently positive, and people predicted to be positive, with COVID-19 over a 4-week time horizon.

4 August 2021

ECDC
ECDC and EMA update on COVID-19

This update stresses that full vaccination is key to protecting against serious COVID-19, including disease caused by the Delta variant.

Reuters
WHO calls for halting COVID-19 vaccine boosters in favor of unvaccinated

The World Health Organization is calling for a halt on COVID-19 vaccine boosters until at least the end of September, its head Tedros Adhanom Ghebreyesus said on Wednesday, as the gap between vaccinations in wealthy and poor countries widens.

27 July 2021

Science Daily
How relaxing COVID-19 restrictions could pave the way for vaccine resistance

This article describes how we are in an 'arms race' with the virus and how rising cases could provide opportunities for it to evolve into even more transmissible variants.

26 July 2021

ECDC
Rapid Risk Assessment: COVID-19 outbreaks in long-term care facilities in the EU/EEA in the context of current vaccination coverage

The BMJ
Long covid—mechanisms, risk factors, and management

This review summarizes studies of the long term effects of covid-19 in hospitalized and non-hospitalized patients and describes the persistent symptoms they endure. Risk factors for acute covid-19 and long covid and possible therapeutic options are also discussed.

23 July 2021

WHO Europe
SARS-CoV-2 Delta variant now dominant in much of European region; efforts must be reinforced to prevent transmission, warns WHO Regional Office for Europe and ECDC

Dr Kluge has a clear message for those countries in the Europe region easing public health and social measures. “WHO recommends that countries increase access to free of charge testing, expand sequencing, incentivize quarantine for contacts and isolation for confirmed cases, strengthen contact tracing to break chains of transmission and ensure those most at risk among our populations are vaccinated.”

22 July 2021

ECDC
Partial COVID-19 vaccination, vaccination following SARS-CoV-2 infection and heterologous vaccination schedule: summary of evidence

This document provides a review of evidence on three topics of interest (effectiveness of partial vaccination, immunogenicity and effectiveness of vaccination for previously infected individuals and safety and immunogenicity of heterologous schedules) to inform ongoing decision-making in relation to national vaccination policies and strategies in the European Union and European Economic Area (EU/EEA) countries.

European Commission
Coronavirus: Commission steps up research funding with €120 million for 11 new projects to tackle the virus and its variants

The Commission has short-listed 11 new projects worth €120 million from Horizon Europe, the biggest European research and innovation programme (2021-2027), for supporting and enabling urgent research into the coronavirus and its variants. The 11 short-listed projects involve 312 research teams from 40 countries, including 38 participants from 23 countries outside of the EU.
Read more about the projects here.

16 July 2021

ECDC
SARS-CoV-2 resurgence in EU and EEA related to relaxation of non-pharmaceutical interventions and increasing spread of Delta variant

There has been a 64.3% increase of weekly COVID-19 cases compared to last week, according to ECDC’s epidemic intelligence and TESSy data reported by EU and EEA countries, as of 15 July 2021. 

EUPHA
COVID-19 Response and Preparedness Seminar Series Webinar 1: TRIPS - recording available

The European Public Health Association (EUPHA) in collaboration with the French Public Health Association (Société Française de Santé Publique) (SFSP), and with the support of the EUPHA Health technology assessment section (EUPHA-HTA), are organising a series of events to raise awareness and to share the knowledge of experts on key aspects regarding: COVID-19 Preparedness and Response.

The first webinar of this series took place on July 6.
 The speakers presented and discussed the Trade-Related Aspects of Intellectual Property Rights (#TRIPS) Agreement, the relevance of a temporary waiver and of voluntary licensing, as well as knowledge transfer and vaccine distribution mechanisms. This first seminar also focused on the role of the European Union and of its Member States regarding these issues.

14 July 2021

EMA
EMA and ECDC update on COVID-19

10 July 2021

European Commission
Statement by President von der Leyen on the EU reaching the milestone of vaccine deliveries to vaccinate 70% of EU adults

8 July 2021

ECDC
COVID-19 in children and the role of school settings in transmission - second update

The aim of this document is to provide an update on the knowledge surrounding the role of children in the transmission of SARS-CoV-2 and the role of schools in the COVID-19 pandemic, focusing in particular on the experience in EU/EEA countries since the beginning of the pandemic. This document also addresses transmission to and from staff in school settings, school-related mitigation measures including risk communication, testing, contact tracing, and the effectiveness and impacts of school closures. 

1 July 2021

European Commission
EU Digital COVID Certificate enters into application in the EU

As of July 1st, the EU Digital COVID Certificate Regulation enters into application. This means that EU citizens and residents will now be able to have their Digital COVID Certificates issued and verified across the EU. 21 Member States as well as Norway, Iceland and Liechtenstein had already started to issue certificates ahead of today's deadline, and five EU countries are starting today.

EUPHA, EUPHA-HTA, French Piblic Health Association
COVID-19 Response and Preparedness Seminar Series: TRIPS Waiver, Knowledge Transfer and Vaccine Distribution - 6 July

The European Public Health Association (EUPHA) in collaboration with the French Public Health Association (Société Française de Santé Publique) (SFSP), and with the support of EUPHA’s Health Technology Assessment Section (EUPHA-HTA), are organising a series of events to raise awareness and to share the knowledge of experts on key aspects regarding:
COVID-19 Preparedness and Response.
We are delighted to announce the first webinar of this series will take place on:
July 6, at 3:30 – 5 pm CEST (Brussels, Paris, Amsterdam) / 9:30 – 11 am EDT (New York)

Register now:  https://bit.ly/3wYgUTP

23 June 2021

ECDC
Threat Assessment Brief: Implications for the EU/EEA on the spread of the SARS-CoV-2 Delta (B.1.617.2) variant of concern

The aim of this threat assessment brief is to assess potential public health implications of the spread of the SARS-CoV-2 Delta (B.1.617.2) variant of concern (VOC) for the European Union and European Economic Area (EU/EEA). 

17 June 2021

Resolve to Save Lives, Surgo Ventures
Increasing COVID-19 Vaccine Uptake - A Four-Step Framework to Promote Access, Acceptance and Equity

This guide provides a framework for identifying and mapping the most useful data sources onto learnings from community engagement to continuously build context-specific interventions and evaluate your success.

14 June 2021

ECDC
Overview of the implementation of COVID-19 vaccination strategies and deployment plans in the EU/EEA

This report provides an updated overview of the progress of national COVID-19 vaccination strategies in EU/EEA countries, including updates on: vaccine uptake overall and by target group; current vaccination phases and priority groups, as well as any adjustments made to priority groups during the rollout; vaccination strategies and policies in place; and the use of vaccination certificates and challenges countries face with the rollout and good practices to mitigate these challenges.

European Commission
EU clears way for the EU Digital COVID Certificate


Today, the Presidents of the three EU institutions, the European Parliament, the Council of the EU and the European Commission attended the official signing ceremony for the Regulation on the EU Digital COVID Certificate, marking the end of the legislative process. 

10 June 2021

European Parliament
Parliament calls for COVID-19 vaccine patent waiver

To accelerate global vaccine rollout, MEPs demand the temporary lifting of intellectual property rights protection for COVID-19 vaccines.

ECDC
Rapid risk assessment: Assessing SARS-CoV-2 circulation, variants of concern, non-pharmaceutical interventions and vaccine rollout in the EU/EEA, 15th update

The Lancet Infectious Diseases
Should we vaccinate children against SARS-CoV-2?

"There might be a case for vaccinating children in the not-too-distant future. However, whether at present the children of high-income countries should be prioritised for vaccination over vulnerable adults in LMICs is a matter for serious ethical and practical debate."

9 June 2021

European Parliament
Parliament gives its final green light to the EU Digital COVID Certificate

MEPs completed today the legislative work on the EU digital COVID Certificate package to facilitate travel within the EU and contribute to the economic recovery. What you need to know:

  • The certificate will be issued free of charge by national authorities and be available in either digital or paper format containing a QR code.
  • The document will certify that a person has been vaccinated against COVID-19, has a recent negative test result or has recovered from the infection. In practice, these will be three distinct certificates.
  • A common EU framework will make certificates interoperable and verifiable across the European Union, as well as prevent fraud and forgery.
  • The system will apply from 1 July 2021 and be in place for 12 months. The certificate will not be a precondition for free movement and will not be considered a travel document.

8 June 2021

WHO
Virtual press briefing on COVID-19: situation in the WHO European Region

When: Thursday 10 June 2021, 11:00 Central European Summer Time (CEST)
WHO/Europe will hold its regular virtual press briefing with Dr Hans Henri P. Kluge, WHO Regional Director for Europe, and technical experts. The briefing will present a situation update on COVID-19 in the WHO European Region and answer media questions.
The virtual press briefing will be broadcast live on WHO/Europe’s Facebook account  and on its Twitter profile

4 June 2021

The BMJ Opinion
Coordination was the right path for the EU’s vaccine strategy, but lessons need to be learned

'It seems clear that future pandemics and other cross-border health threats will require increased cooperation on a European level—not just in the context of vaccines, but also in other areas of health policy. The European Commission has started to promote the idea of a European Health Union and individual member states are beginning to acknowledge that the bloc should be granted more power when it comes to health matters.'

Revolve to Save Lives by Vital Strategies
COVID-19: In-Depth Science Review

This science review is a snapshot of the new and emerging scientific evidence related to COVID-19 during the period specified. It is a review of important topics and articles.

3 June 2021

ECDC
Reducing COVID 19 transmission and strengthening vaccine uptake among migrant populations in the EU/EEA

This report presents evidence on the impact of COVID-19 on migrant populations in EU/EEA countries; risk factors for increased COVID-19 exposure in migrant populations; and considerations for ensuring equitable access to the COVID-19 vaccine for migrant populations.

1 June 2021

ECDC
Interim public health considerations for COVID-19 vaccination of adolescents in the EU/EEA

This technical report provides a set of interim public health considerations to support EU/EEA public health authorities taking decisions on the administration of COVID-19 vaccines to adolescents (12- to 18-year-olds).
The focus of this document is on the overall potential public health impact, rather than on the individual benefits and risks, of COVID-19 vaccination in adolescents.

31 May 2021

European Commission
Coronavirus: Commission proposes update to coordinated travel measures ahead of the summer

The European Commission has proposed an update to the Council Recommendation on the coordination of free movement restrictions in the EU, which were put in place in response to the COVID-19 pandemic.

Joint Research Centre
COVID-19: How a better understanding of airborne transmission is the key to break the chain of infection

In a new study published in May, JRC scientists propose to merge the two non-contact transmission modes, large-droplet and aerosol, into a unique non-contact airborne transmission mode. It is, according to them, essential to break the chain of infection, 

28 May 2021

The BMJ
Suspend intellectual property rights for covid-19 vaccines

'As we enter into a new era of global pandemics, we must fundamentally rethink the global intellectual property system. The ability to respond swiftly to global crises cannot be left to a handful of private companies in a few wealthy countries. We need a more cooperative global response to this and future public health emergencies.'

27 May 2021

ECDC
COVID-19 situation update for the EU/EEA, as of 27 May 2021

26 May 2021

The BMJ
What does it mean to engage the public in the response to covid-19?

In this paper, the authors explain how governments and other authorities should respond to calls for public engagement in covid-19 response and recovery.

24 May 2021

Journal of Epidemiology and Community Health
Importance of population-based longitudinal studies to understanding the impact of COVID-19

The author discusses some of the important dimensions of the COVID-19 pandemic that population-based longitudinal studies are well placed to study.

20 May 2021

European Parliament
Getting a patent waiver is not enough, says WTO chief to Trade Committee

WTO Director-General Dr Ngozi Okonjo-Iweala said: “Getting the Intellectual Property rights waiver for vaccines will not be enough”. She listed three other routes: reducing export restrictions and reinforcing supply chains for vaccines, working with manufacturers to expand production, including in emerging countries with idle capacity such as Indonesia, South Africa, Thailand or Bangladesh, and transferring the necessary technology and expertise to produce the complicated vaccines.

WHO/Europe
Statement – COVID-19: A fragile progress

Dr Hans Henri P. Kluge, WHO Regional Director for Europe, highlights the progresses made in the fight again COVID-19, but also stresses the fragility of the whole process.

ECDC
The use of antibody tests for SARS-COV-2 in the context of Digital Green Certificates

This brief technical note was developed at the request of the European Commission to inform the discussion on Digital Green Certificates to facilitate the safe and free movement of citizens within the EU during the COVID-19 pandemic.

19 May 2021

European Parliament
EU Covid-19 Certificate: a European solution for free testing is needed

EP negotiators want to use the Emergency Support Instrument in order to provide citizens with accessible and free of charge testing for the purpose of the new EU Covid-19 certificate. 

ECDC
ECDC releases new dashboard on SARS-CoV-2 variants

A new dashboard released by ECDC now provides an overview of the proportion of SARS-CoV-2 variants of concern and variants of interest among sequenced samples in European Union (EU) and European Economic Area (EEA) countries, as well as sequencing volumes. It complements the data published in ECDC’s weekly country overview report. 

13 May 2021

The BMJ
Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on covid-19 related symptoms, hospital admissions, and mortality in older adults in England: test negative case-control study

In conclusion, vaccination with either one dose of BNT162b2 or ChAdOx1-S was associated with a significant reduction in symptomatic covid-19 in older adults, and with further protection against severe disease. Both vaccines showed similar effects. 

11 May 2021

International Health
Institutional and behaviour-change interventions to support COVID-19 public health measures: a review by the Lancet Commission Task Force on public health measures to suppress the pandemic

'To mitigate the negative impact of COVID-19 restrictions and build preparedness for future pandemics, political leaders at local, regional and global levels must weigh up the benefits and harms of restrictions on individual freedoms, tackle existing and emerging inequities, provide clear, consistent guidance to the public and strengthen capacity in research and the application of the analytical and behavioural sciences.'

10 May 2021

Nature
A global database of COVID-19 vaccinations

The authors present the Our World in Data COVID-19 vaccination dataset, a global public dataset that tracks the scale and rate of the vaccine rollout across the world. This resource aids policymakers and researchers in understanding the rate of current and potential vaccine rollout; the interactions with non-vaccination policy responses; the potential impact of vaccinations on pandemic outcomes such as transmission, morbidity and mortality; and global inequalities in vaccine access.

6 May 2021

ECDC
Overview of the implementation of COVID-19 vaccination strategies and vaccine deployment plans in the EU/EEA

This report provides an updated overview of the progress of national COVID-19 vaccination strategies in EU/EEA countries, including updates on: vaccine uptake overall and by target group; current vaccination phases and priority groups, as well as any adjustments made to priority groups during the rollout; vaccination strategies and policies in place; and the use of vaccination certificates and challenges countries face with the rollout and good practices to mitigate these challenges.<a href="https://www.the